Norroy Showcased Three Oral Presentations at SNMMI 2025, Unveiling Next-Generation Radiopharmaceuticals for Renal Cancer and Beyond

Read More

Event Preview | Symposium of Clinical Strategies for Precision Radiopharmaceuticals

Read More

Norroy Bioscience Presents Promising Renal Cancer Imaging Data at 2025 ASCO Annual Meeting

Read More

Norroy Bioscience Opens New Research Institute in Nanjing, China

Read More

Norroy Bioscience Completes Enrollment for Phase I/II Clinical Trial of In-House Developed Therapeutic Radiopharmaceutical 177Lu-NYM032

Read More

Norroy Completes Phase I/II Clinical Trial of 68Ga-NYM005, a Novel CAIX-Targeted PET Imaging Agent

Read More

EJNMMI: Preliminary Study Results of Norroy’s New Generation PSMA-Targeted Theranostic Radiopharmaceutical Released

Read More

JNM: Norroy Announces First-in-Human Clinical Results of Second-Generation Small-Molecule Radiopharmaceutical for Kidney Cancer

Read More

Norroy's Kidney Cancer Radiopharmaceutical 18F-NYM005 Receives IND Approval from the U.S. FDA

Read More